Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Revenue (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Revenue for 9 consecutive years, with $887000.0 as the latest value for Q1 2026.

  • For Q1 2026, Revenue fell 91.11% year-over-year to $887000.0; the TTM value through Mar 2026 reached $63.5 million, up 146.85%, while the annual FY2025 figure was $72.6 million, 105.77% up from the prior year.
  • Revenue hit $887000.0 in Q1 2026 for Bicycle Therapeutics, down from $48.0 million in the prior quarter.
  • Across five years, Revenue topped out at $48.0 million in Q4 2025 and bottomed at $887000.0 in Q1 2026.
  • Average Revenue over 5 years is $8.8 million, with a median of $5.4 million recorded in 2023.
  • Year-over-year, Revenue surged 1193.28% in 2025 and then crashed 91.11% in 2026.
  • Bicycle Therapeutics' Revenue stood at $8.4 million in 2022, then plummeted by 36.54% to $5.3 million in 2023, then crashed by 30.44% to $3.7 million in 2024, then soared by 1193.28% to $48.0 million in 2025, then plummeted by 98.15% to $887000.0 in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $887000.0, $48.0 million, and $11.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.